Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Operating Expenses (2020 - 2025)

Bioventus (BVS) has disclosed Operating Expenses for 6 consecutive years, with $82.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 4.68% year-over-year to $82.8 million, compared with a TTM value of $323.1 million through Dec 2025, down 8.67%, and an annual FY2025 reading of $316.3 million, down 10.73% over the prior year.
  • Operating Expenses was $82.8 million for Q4 2025 at Bioventus, up from $81.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $100.7 million in Q2 2024 and bottomed at $35.6 million in Q2 2021.
  • Average Operating Expenses over 5 years is $81.7 million, with a median of $82.5 million recorded in 2025.
  • The sharpest move saw Operating Expenses soared 162.76% in 2022, then decreased 18.69% in 2023.
  • Year by year, Operating Expenses stood at $88.7 million in 2021, then decreased by 1.03% to $87.8 million in 2022, then dropped by 7.08% to $81.5 million in 2023, then grew by 6.47% to $86.8 million in 2024, then decreased by 4.68% to $82.8 million in 2025.
  • Business Quant data shows Operating Expenses for BVS at $82.8 million in Q4 2025, $81.6 million in Q3 2025, and $82.3 million in Q2 2025.